[ad_1]
On Monday, Moderna Inc. claimed that its Omicron-tailored vaccines had improved immune responses against BA.4/5 sub-variants. when administered as a booster dose, compared to its initial shot. The company found this in a mid-to-late stage study.
Data demonstrates that in adults who had been vaccinated and given booster shots, both of Moderna’s Omicron-tailored vaccines, mRNA-1273.214 and mRNA-1273.222, produced a higher antibody response against BA.4/5 subvariants than its original vaccine.
In an analysis of about 40 participants, Moderna claimed that levels of neutralising antibody response decreased nearly 5-fold against the emerging sub-variant BQ.1.1 when compared with BA.4/5, even though the virus neutralising activity still remained “robust.”
Moderna’s competitor Pfizer Inc. and its German partner, BioNTech SE, reported earlier that after one month, their Omicron-tailored shot, which targets the BA.4/5 subvariants, produced a stronger antibody response in older adults than the original shot.
Omicron-tailored shots made by Moderna and Pfizer have already received US approval for both adults and children as young as five years old based on data from pre-clinical studies. As of 9 November, nearly 31.4 million Americans had received the updated vaccine, with about 5.1 million receiving it just last week, according to government statistics.
(With inputs from Reuters)
Download The Mint News App to get Daily Market Updates.
[ad_2]